340B Drug Pricing Program

The American Hospital Association warns against accelerating clawbacks and reducing reimbursements under CMS’s 2027 OPPS rule.

The drug maker says data about individual transactions, including patient, provider, service, and payment details, is needed to meet obligations under the Inflation Reduction Act.

A demand to turn over a clinical-level data mandate in less than a week has roiled the sector, raising alarms about access to 340B discounts and the future of the safety net program.

The plaintiffs allege that the company and its affiliates diverted funds that should have been passed through to hospitals participating in the drug-pricing program.

In a high-stakes struggle over the fate of the popular drug pricing program, neither the Trump administration nor safety-net hospital groups seem willing to cede the field.

The RFI is the Trump administration’s next move to get its drug pricing rebate program back on track after hospital groups blocked it last year.

Under HHS’s rebate model program, safety-net providers would have to pay millions upfront for drugs that would otherwise be spent on low-income patients.